The Quantellect read.As of Nov 19, 2026, 10 active firms cover Oric Pharmaceuticals Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $15.00 to $27.00, a moderate spread. The average target of $22.50 sits 195% above the current $7.63. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.40 next quarter toward $-1.69 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.50
+194.9% upside
Average target across 10 active firms as of Nov 19, 2026 vs $7.63 current
Highest Target$27.00
Average Target$22.50
Lowest Target$15.00
Detailed analyst forecasts for ORIC
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate ORIC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ORIC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.40
Range $-0.47 – $-0.34 · 13 analysts · +32% YoY
Next period, 13 analysts expect Oric Pharmaceuticals Inc to earn $-0.40 a share (range $-0.47 – $-0.34), versus $-0.30 a year earlier. Full-year consensus is $-1.49, growing to $-1.69 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 13 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oric Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ORIC.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$18.00+135.9% to target
Overall win rate
53%
+ Follow
#2
David Nierengarten
Wedbush · Rank #24
Buy
$17.00+122.8% to target
Overall win rate
48%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #171
Buy
$26.00+240.8% to target
Overall win rate
48%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$27.00+253.9% to target
Overall win rate
42%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$16.00+109.7% to target
Overall win rate
38%
+ Follow
ORIC stock forecast FAQ
What is ORIC's average 12-month price target?+
The 10 active firms with a live target average $22.50 for Oric Pharmaceuticals Inc over the next 12 months, ranging from a $27.00 high to a $15.00 low, as of Nov 19, 2026.
Is ORIC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ORIC?+
The Street-high target is $27.00 (HC Wainwright & Co.), and the Street-low is $15.00 (Goldman Sachs). The average of all 10 active-firm targets is $22.50.
How many active Wall Street firms cover ORIC?+
10 active firms have a recognized rating on Oric Pharmaceuticals Inc as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ORIC?+
Among analysts who currently cover ORIC, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $18.00 target.
What is Oric Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.40 per share (range $-0.47 – $-0.34) across 13 analysts. Full-year EPS is projected at $-1.49, rising to $-1.69 the following year.
How much revenue is Oric Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ORIC lately?+
As of Nov 19, 2026, 10 of 10 active firms rate ORIC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ORIC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.